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Abstract  
Introduction: pain management is an important and challenging issue in emergency medicine. Despite the 
conduct of several studies on this topic, pain is still handled improperly in many cases. 
Objective: This study investigated the effectiveness of low-dose IN ketamine administration in reducing the 
need for opiates in patients in acute pain resulting from limb injury.  
Method: This randomized, double-blind, placebo-controlled trial was conducted to assess the possible effect 
of low-dose intranasal (IN) ketamine administration in decreasing patients' narcotic need. Patients in 
emergency department suffering from acute isolated limb trauma were included. One group of patients 
received 0.5 mg/kg intravenous morphine sulfate and 0.02 ml/kg IN ketamine. The other group received the 
same dose of morphine sulfate and 0.02 ml/kg IN distilled water. Pain severity was measured using the 11 
points numerical rating scale at 0, 10, 30, 60, 120, and 180 minutes. 
Results: Ninety-one patients with mean age of 31.59 ± 11.33 years were enrolled (38.8% female). The number 
of requests for supplemental medication was significantly lower in patients who received ketamine (12 
patients (30%)) than those who received placebo (27 patients (67.5%)) (p = 0.001). 
Conclusion: It is likely that low-dose IN ketamine is effective in reducing the narcotic need of patients suffering 
from acute limb trauma. 
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INTRODUCTION
Pain is one of the most common complaints among 
patients visiting the emergency department (ED); 
more than half of patients visiting ED complain 
about pain to some extent (1, 2). Hence, pain 
management is an important and challenging issue 
in emergency medicine. Despite the conduct of 
several studies on this topic, pain is still handled 
improperly in many cases (3-6). There are several 
analgesics for pain control, and opiates are still 
among the oldest and most commonly used 
medications (7, 8). Despite the strong analgesic 
effect of opiates, their possible side effects such as 
nausea, vomiting, hypoventilation, hypotension, 
constipation, and risk of dependence limit their use 
in some cases. In some instances, a high dose of 
opiate may be required, that could lead to 
increased risk of complications (9). Accordingly, 
many surveys have been conducted to find an 
alternative to opiates or an adjuvant medication 
that reduces the opioid dose required. An approved 
method is the use of sedatives (e.g., 
benzodiazepines) for breakthrough acute pain, 
which unfortunately is associated with 
complications such as increased central nervous 
system depression and hypoventilation (10, 11). 
So, the search for an alternative analgesic agent is 
still on, at least for cases with the risk of 
complication and no clinical response to opiates 
(7). 
Ketamine, a derivative of phencyclidine, is well-
known as a dissociative anesthetic agent, available 
in various medicinal forms. It is among the few 
anesthetics that provide all the three components 
of desirable anesthesia, namely anti-nociception, 
immobility, and amnesia (12). Based on available 
evidence, the intranasal (IN) form of ketamine has 
adequate bioavailability and desirable clinical 
effect compared with other non-intravenous 
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formulations (13). This study investigated the 
effectiveness of low-dose IN ketamine 
administration in reducing the need for opiates in 
patients in acute pain resulting from limb injury. 
METHODS 
Study design 
This was a randomized, double-blind, placebo-
controlled trial (phase 3) conducted from March 
2015 to June 2016 in the academic ED of Besat 
Hospital, Army University of Medical Sciences, 
Tehran, Iran. The protocol of the study was 
approved by the ethics committee of Army 
University of Medical Sciences on February 19, 
2013, and ID:9209 was assigned. The investigators 
were committed to the Helsinki Declaration 
principles at all stages of this study. Written 
consent was obtained from all patients, and they 
were free to leave the study at any time. 
Study population 
Patients with acute isolated limb trauma, visiting 
the ED, were enrolled based on inclusion and 
exclusion criteria using convenience sampling 
technique. Patients of either gender older than 18 
years with limb pain resulting from traumatic 
injuries within the last 24 hours and baseline 
numeric rating scale (NRS) ≥ 7 were included. The 
exclusion criteria were as follows: open fracture; 
closed fracture in more than one site; fracture plus 
dislocation; acute traumatic pain in more than two 
limbs; unstable hemodynamics (blood pressure 
(BP) < 90/60 mmHg or BP > 160/100 mmHg, pulse 
rate (PR) > 120/min or PR < 60/min); Glasgow 
Coma Scale (GCS) < 15; non-limb traumatic injuries 
(head, neck, chest, etc.); pregnancy; history of 
allergic reaction to ketamine or morphine; patients 
reluctant to participate; patients leaving the 
hospital for any reason within three hours after 
drug administration. 
According to 𝑛 =
(𝑍
1−
𝛼
2
+𝑍1−𝛽)
2
× 𝜎2
(µ1−µ2)2
, at least 38 patients 
were needed in each group, namely treatment and 
placebo, for making a statistical comparison (α = 
0.05, 𝑍_(1 − 𝛼/2) = 1.96, power = 0.8, 𝑍1−𝛽 = 0.84, 
σ = 2, µ1 = 7, µ2 = 5.7) (14). 
Randomization and blinding 
Patients were randomly assigned to ketamine (K) 
and placebo (P) groups using computer-assisted 
randomization table. Similar containers (in terms 
of size and color) were filled with ketamine and 
distilled water, marked with computer-generated 
random codes comprising of a Latin word and four 
digits, and allocated to the ketamine (K) or placebo 
(P) groups.  
The injection team and patients were unaware of 
the mechanism of assigning the codes. A paper 
packet, containing a sheet with a Latin word and 
four digits written on it, was provided for each 
sample. The codes were equally assigned to the 
treatment and placebo groups. The researcher 
picked a packet by chance and administered the 
coded medicine. 
Intervention 
The administered medicines in each group were: 
Ketamine Group (K): intravenous (IV) morphine 
sulfate (0.05 mg/kg) and 0.02 ml/kg IN ketamine 
solution (containing 50 mg/ml ketamine), using a 
dropper; Placebo Group (P): IV morphine sulfate 
(0.05 mg/kg) plus 0.02 ml/kg IN distilled water, 
using a simple dropper prepared for the 
intervention. We measured the volume needed for 
each patient (0.02 ml/kg) with a syringe and then 
administered the volume with the dropper to the 
patient.  
Ketamine bioavailability was determined to be 
around fifty percent in past studies (15). We 
administered 1 mg/kg (0.02 ml/kg) IN ketamine to 
patients in the ketamine group. We expected this 
dose to be bioequivalent to 0.5 mg/kg IV dose. If 
any patient requested more analgesics at any time 
after 10 minutes of primary drug administration, 
we gave them 0.05 mg/kg IV morphine sulfate. 
Outcome 
The primary outcome was a request for a 
supplemental analgesic. The secondary outcomes 
included NRS reduction, hemodynamic changes, 
and side effects in both groups. Information 
regarding making or not making a request and time 
of the request for a supplemental analgesic were 
recorded.  
NRS was used to measure the severity of pain in the 
current survey. This scale can be used for verbal or 
visual expression of pain level. In this self-report 
battery, the patient scores his/her severity of pain 
on a scale from 0 (without pain) to 10 (the most 
severe pain). The patient can report the pain 
verbally, by making a mark on the scale, or by 
pointing with fingers. NRS was measured at 10, 30, 
60, 120, and 180 minutes after drug 
administration.  
Age, gender, systolic blood pressure (SBP), heart 
rate (HR), arterial oxygen saturation (O2sat), and 
consciousness level were also recorded at 10, 30, 
and 60 minutes after drug administration. Any 
adverse effects that occurred within three hours 
after drug administration were noted. 
Statistical analysis 
The collected data were analyzed using statistical 
package for social sciences (SPSS) software version 
18.0 (SPSS Inc., Chicago, USA). Qualitative data 
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were analyzed with the chi-square test. For 
quantitative data analysis, parametric and non-
parametric data were first specified with 
Kolmogorov-Smirnov test. Then, parametric and 
non-parametric data were analyzed with t-test and 
Mann-Whitney test, respectively. One-way analysis 
of variance (ANOVA) and Kruskal-Wallis test were 
used for the analysis of parametric and non-
parametric longitudinal data (SBP, HR, O2sat, and 
NRS), respectively. P-values less than 0.05 were 
considered significant. 
RESULTS 
Demographic and baseline findings 
The CONSORT flowchart of the studied patients is 
presented in figure 1. Seventeen out of the 97 
patients admitted to the ED with limb injuries that 
required analgesics were excluded. Finally, 80 
patients with mean age of 31.59 ± 11.33 years were 
enrolled (38.8% female) and randomly assigned to 
either the K group (n = 40) or P group (n = 40). 
The demographic and baseline characteristics of 
the participants are summarized in table 1. The 
mean age (p = 0.899) and sex ratio (p = 0.818) of 
the two groups were not statistically significantly 
different. The mean baseline HR, O2sat, and GCS 
were not significantly different between the two 
groups (p > 0.05), but the mean NRS (K: 8.50 vs. P: 
9.05; p = 0.032) and SBP (K:111.50 vs. P:117.25; p 
= 0.020) were significantly lower in the ketamine 
group compared with the placebo group at 
baseline.  
Primary outcomes 
The number of requests for a supplemental 
analgesic was significantly lower in patients who 
received ketamine (12 patients (30.0%)) than 
those who received placebo (27 patients (67.5%)) 
(p = 0.001). The difference regarding the mean 
time of the request for a supplemental medication 
(minutes after the first morphine injection), 
although clinically apparent, was not statistically 
significant between the groups (K: 60.83 ± 39.19 vs. 
P: 37.41 ± 23.95; p = 0.059).  
Secondary outcomes 
The data concerning the mean NRS by time for both 
groups are presented in figure 2. The difference in 
the mean NRS at 30 min (K: 5.08 vs. P: 6.2; p = 
0.027), 60 min (K: 3.28 vs. P: 4.6; p = 0.003), and 
120 min (K: 2.38 vs. P: 2.80; p = 0.048) was 
significantly lower in the ketamine than the 
placebo group. There was no significant difference 
between the two groups at other checkpoints. 
Based on the Friedman test, the mean NRS changes 
from 0 to 180 min was significant in both groups 
(K, p < 0.001; P, p < 0.001). The mean NRS reduced 
in both groups with time. The differences in the 
reduced mean NRS within the different time 
intervals were not significant between the two 
groups (table 2). 
The mean SBP at 10 min (K: 111.63 vs. P: 119.50; p 
= 0.004) and 30 min (K: 112.75 vs. P: 117.00; p = 
0.0243) was significantly lower in the ketamine 
group than the placebo. This difference was not 
significant at 60 min between the two groups (p = 
0.643) (table 3). According to the Friedman test 
results, the changes in the mean SBP from 0 to 180 
min was significant in the placebo group (p = 
0.001) but not in the ketamine group (p = 0.775). 
The mean SBP decreased in the placebo and 
 
Figure 1: CONSORT flowchart of studied patients 
 
 
 
Table 1: Baseline characteristics of studied patients 
Variables 
Placebo 
(n = 40) 
Ketamine 
(n = 40) p 
Mean ± SD 
Female (%) 40.0 37.5 0.818 
Age (year) 31.75 ± 12.08 31.43 ± 10.7 0.899 
NRS (number) 9.05 ± 1.13 8.50 ± 1.16 0.032 
SBP (mmHg) 117.25 ± 9.60 111.50 ± 10.20 0.020 
HR (beat/min) 83.90 ± 6.46 81.60 ± 6.60 0.161 
O2 sat (%) 98.80 ± 0.82 98.53 ± 0.91 0.112 
NRS, numeric rating scale; SBP, systolic blood pressure; HR, heart rate; 
GCS, Glasgow coma scale 
 
 
 
 
 
 
 
 
 
Figure 2: Mean of numeric rating scale at different 
checkpoints in the ketamine and placebo groups 
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increased in the ketamine group with time. The 
differences in HR at 10 min (p = 0.686), 30 min (p = 
0.117), and 60 min (p = 0.160) were not significant 
between the two groups (table 4). According to the 
Friedman test results, the changes in the mean HR 
from 0 to 180 min was significant in both placebo 
(p < 0.001) and ketamine groups (p < 0.001). The 
mean HR reduced in both groups with time. The 
between-group differences were not significant in 
terms of O2sat at 10 min (p = 0.086), 30 min (p = 
0.327), and 60 min (p = 0.278) (table 3). According 
to the Friedman test results, changes in the mean 
O2sat from 0 to 180 minute was not significant in 
both placebo (p = 0.159) and ketamine groups (p = 
0.672). 
Totally, 16 adverse side effects due to the drugs 
were observed in 13 patients in both groups. 
Among them, 7 complications were in the placebo 
group (vomiting: 4, sneezing: 1, and coughing: 2) 
and 9 in the ketamine group (vomiting: 5, sneezing: 
2, and coughing: 1). These complications occurred 
in 7 cases (17.5%) in placebo and 6 cases (18%) in 
ketamine group. There was no significant 
difference in the incidence of side effects between 
the two groups (p = 0.769). The most frequent side 
effect of the medication was vomiting, seen in 9 out 
of 16 cases (56.25%).  
DISCUSSION 
Considering the results, it seems that low-dose IN 
ketamine administration could reduce the need for 
opiates in patients in acute pain resulting from limb 
injury, and its use in ED would be rational. 
Previous studies strongly supported the 
effectiveness of low-dose ketamine administration 
via various routes in reducing pain (16-21). In an 
observational study, Yeaman et al. investigated the 
effect of IN ketamine on pain reduction in acute 
limb injuries in children aged 3–13 years with 
moderate-to-severe degrees of pain. They reported 
that the median pain score decreased from 74.5 to 
30 mm in 30 min. In 24 patients, the median pain 
score was 25 mm after continuing measurement 
until 60 min. The rate of satisfaction of anti-
nociception was 83%, and 8 patients (33%) 
received a supplemental opioid analgesic. In total, 
28 cases with side effects were reported; however, 
all of them were mildly severe (14). Shimonovich et 
al. also conducted a survey to assess the efficacy of 
IN ketamine compared with IV and intramuscular 
(IM) morphine for acute traumatic pain 
management in the ED. They found that IN 
ketamine provided clinically-comparable results to 
those of IV morphine with regard to time to onset 
as well as maximal pain reduction. They concluded 
that IN ketamine has efficacy and safety 
comparable to IV and IM morphine (22). 
Increased BP is among the known side effects of 
ketamine (12, 23-25). In the current study, the 
mean BP at all the mentioned time intervals was 
higher in the placebo than the ketamine group. 
However, the BP increased in the ketamine and 
decreased in the placebo group with time, and it 
was statistically significant in the placebo group. 
On the other hand, the modest BP reduction in the 
placebo group can be attributed to the effects of 
using morphine and subsequent pain relief (7). 
Given the use of low-dose ketamine, IN 
Table 2: Mean numeric rating scale changes within the different time intervals 
p-value 
Placebo 
(n = 40) 
Ketamine 
(n = 40) 
Time interval (minutes) 
0.917 −1.38 ± 1.35 −1.55 ± 1.93 0–10 
0.315 −2.85 ± 1.78 −3.43 ± 2.21 0–30 
0.057 −4.45 ± 1.99 −5.23 ± 1.90 0–60 
0.864 −6.25 ± 1.71 −6.13 ± 1.91 0–120 
0.174 −7.03 ± 1.58 −6.60 ± 1.68 0–180 
 
Table 3: Mean heart rate (HR), systolic blood pressure (SBP), and oxygen saturation (O2sat) at different checkpoints in the ketamine 
and placebo groups 
p-value 
Checkpoints Groups 
Variable 
60 min 30 min 10 min 
0.775 112.13 ± 9.99 112.75 ± 8.91 111.63 ± 11.12 Ketamine 
Systolic blood pressure 0.001 113.50 ± 8.64 117.00 ± 7.91 119.50 ± 10.61 Placebo 
- 0.643 0.043 0.004 p-value 
<0.001 76.08 ± 7.67 78.00 ± 6.42 80.58 ± 6.59 Ketamine 
Heart rate <0.001 78.63 ± 4.24 80.58 ± 5.47 81.35 ± 5.52 Placebo 
- 0.160 0.117 0.686 p-value 
0.672 98.35 ± 0.95 98.33 ± 1.07 98.43 ± 0.96 Ketamine 
O2 saturation 0.159 98.63 ± 0.87 98.63 ± 0.71 98.78 ± 0.83 Placebo 
- 0.278 0.327 0.086 p-value 
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administration, and simultaneous use of IV 
morphine, it seems that the BP raising effect of 
ketamine was lessened. There was no significant 
between-group difference regarding HR with time; 
however, HR changes with time was significant in 
each group. Increased HR is among the definitive 
side effects of ketamine (17-19). Lower HR in the 
ketamine group than the placebo may due to the 
use of low-dose ketamine and IN administration 
route. 
Previous studies reported low-dose ketamine as 
almost a safe treatment with very few 
complications (14, 16, 17, 26). There was no 
significant between-group difference regarding 
O2sat with time. O2sat drop following ketamine 
administration is a rare phenomenon. This is 
because ketamine does not reduce respiratory 
drive and preserves airway reflexes; incidence of 
laryngospasm typically occurs following boluses of 
ketamine intravenously (7, 18, 23-25). 
Previous studies reported the effectiveness of low-
dose ketamine in reducing the number of requests 
for supplemental analgesics (14, 16, 20). The 
number of analgesic demand was significantly 
higher among the patients receiving placebo. The 
initial NRS was higher in patients requesting a 
supplemental analgesic. Although this difference 
was statistically significant, it was clinically 
insignificant (0.54-unit difference between the two 
groups). On average, analgesic demands were 
made sooner in the placebo than the ketamine 
group; however, this between-group difference 
was not significant. The lower number of analgesic 
demands by the patients in the ketamine group can 
be attributed to the additional effect of IN 
administration of low-dose ketamine. The 
difference in the number of patients developing 
complications was not significant between the two 
groups, and no serious complication was observed 
in them. 
Limitations 
Although the pain score of the patients in the 
ketamine group was lower than that in the placebo 
group, we failed in showing the analgesic 
effectiveness of IN ketamine plus injectable opiates 
due to (i) lower pain score in the ketamine group 
patients at baseline, and (ii) insignificant difference 
in pain reduction at the different time intervals 
between the two groups. To weaken the effect of 
between-group mismatch in the pain score at 
baseline, in addition to comparing the mean pain 
scores at different times in the two groups, their 
difference in pain reduction at different time 
intervals was also compared. However, it did not 
contribute to the absolute reliability of the results.  
CONCLUSIONS 
It is likely that IN administration of low-dose 
ketamine plus IV administration of morphine 
sulfate could reduce the further request for an 
opioid. Administration of this combination does 
not result in any hemodynamic instability or more 
complications than administration of IV morphine 
alone. Given the effect of IN ketamine on the 
reduction of the required opioid dose, 
supplementation of analgesics with it is 
recommended as a rational choice. 
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